ABL Medical Launches SilvrSTAT® in U.S.
ABL Medical, LLC has announced the official launch of its SilvrSTAT® Antibacterial Wound Dressing Gel in the U.S.
According to the press release, SilvrSTAT® is based on the company’s patented nano-molecular silver technology and has United States Food and Drug Administration clearance as a 510(k) medical device. ABL Medical states that SilvrSTAT “results in a 32ppm antibacterial wound dressing gel which provides quick and continuous antibacterial activity allowing for efficient wound management” and “has no known or expected adverse events due to the low 32ppm silver concentration.” ABL Medical promotes SilvrSTAT® as inhibiting the growth of a wide range of bacteria, viruses, yeast, and molds in laboratory tests.
The press release is available through Canada Newswire here.
Share